SpectraScience (SpectraScience) FCF Margin % : 0.00% (As of Sep. 2017)

View and export this data going back to . Start your Free Trial

What is SpectraScience FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SpectraScience's Free Cash Flow for the three months ended in Sep. 2017 was $-0.10 Mil. SpectraScience's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, SpectraScience's FCF Margin % for the quarter that ended in Sep. 2017 was 0.00%.

As of today, SpectraScience's current FCF Yield % is 0.00%.

The historical rank and industry rank for SpectraScience's FCF Margin % or its related term are showing as below:

SCIE' s FCF Margin % Range Over the Past 10 Years
Min: -15040 Med: 0 Max: 0
Current: -15040

SCIE's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -7.45 vs SCIE: -15040.00

SpectraScience FCF Margin % Historical Data

The historical data trend for SpectraScience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience FCF Margin % Chart

SpectraScience Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

FCF Margin %

Get a 7-Day Free Trial

-627.11

-673.75

-27,000.00

-30,260.00

SpectraScience Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
FCF Margin %	Get a 7-Day Free Trial															-9,150.00	-	-	-	-

Competitive Comparison of SpectraScience's FCF Margin %

For the Medical Devices subindustry, SpectraScience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpectraScience's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraScience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SpectraScience's FCF Margin % falls into.

SpectraScience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SpectraScience's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2016 )	/	Revenue (A: Dec. 2016 )
	=	-1.513	/	0.005
	=	-30,260.00 %

SpectraScience's FCF Margin for the quarter that ended in Sep. 2017 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2017 )	/	Revenue (Q: Sep. 2017 )
	=	-0.097	/	0
	=	%

SpectraScience FCF Margin % Related Terms

Thank you for viewing the detailed overview of SpectraScience's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SpectraScience (SpectraScience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121

Website

http://www.spectrascience.com

SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.

Executives

Lowell Giffhorn	officer: CFO	10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines